Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the overall response rate (CR+PR as per IWG 2006) at 6 months in MDS patients, CMML-2 patients, and AML patients with up to 30% bone marrow blasts (previously classified as RAEB-t by the FAB MDS classification), treated with low-dose decitabine who have previously failed therapy with 5-azacitidine.
Inclusion criteria
- Myelodysplastic Syndromes
- Acute Myeloid Leukaemia
- Chronic Myelomonocytic Leukaemia